ValuEngine cut shares of Evoke Pharma (NASDAQ:EVOK) from a sell rating to a strong sell rating in a research note published on Friday.

Several other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Evoke Pharma from a hold rating to a sell rating in a research note on Friday. HC Wainwright set a $9.00 price target on shares of Evoke Pharma and gave the company a buy rating in a research note on Wednesday. B. Riley reaffirmed a buy rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, November 15th. FBR & Co reaffirmed a buy rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Monday, October 30th. Finally, Northland Securities reaffirmed a buy rating and set a $10.00 price target on shares of Evoke Pharma in a research note on Wednesday, October 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Evoke Pharma currently has a consensus rating of Buy and a consensus target price of $9.00.

Evoke Pharma (NASDAQ EVOK) remained flat at $$2.67 during trading on Friday. 27,243 shares of the company traded hands, compared to its average volume of 350,959. Evoke Pharma has a 52 week low of $1.42 and a 52 week high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). During the same quarter in the previous year, the company earned ($0.29) EPS. equities analysts predict that Evoke Pharma will post -1 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. increased its holdings in Evoke Pharma by 14.2% during the third quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after buying an additional 71,022 shares during the period. State Treasurer State of Michigan increased its holdings in Evoke Pharma by 37.0% during the second quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock valued at $1,024,000 after buying an additional 108,034 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Evoke Pharma by 15.1% during the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 68,544 shares during the period. 13.64% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Evoke Pharma (EVOK) Downgraded to Strong Sell at ValuEngine” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/12/02/evoke-pharma-evok-downgraded-to-strong-sell-at-valuengine.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.